Sanctuary Advisors LLC Acquires Shares of 1,597 Ascendis Pharma A/S (NASDAQ:ASND)

Sanctuary Advisors LLC bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,597 shares of the biotechnology company’s stock, valued at approximately $203,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S during the third quarter worth about $30,000. Blue Trust Inc. raised its stake in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares in the last quarter. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Legato Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 134 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald upped their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. TD Cowen dropped their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Wedbush restated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Stock Performance

ASND opened at $155.86 on Thursday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $158.00. The company’s 50 day simple moving average is $136.59 and its 200 day simple moving average is $134.09. The stock has a market capitalization of $9.46 billion, a PE ratio of -21.95 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.